Cybin Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cybin Inc (CYBN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cybin Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 159M vs 82M combined for its competitors (66.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs decelerating (-23.3%) for its tracked peer group.
- Growth: Cybin Inc generated 123.7% revenue growth year over year in Q4 2025, vs 94.2% for its competitors combined.
- Profitability: Its -54.5% net margin compares with -1,030.3% for the peer group.
- Peer revenue share: Cybin Inc accounted for 91.0% of combined revenue among its tracked peer group, up from 89.8% a year earlier.
- Peer differentiation: Revenue per employee of $5.30M compares with $0.17M for the peer group (31.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CYBN Sales vs. its Competitors, Q4 2025
Cybin Inc reported revenue growth of 123.74 % year on year in Q4 2025, above its competitors' combined revenue growth of 94.23 %.
With a net margin of -54.45 %, Cybin Inc achieved higher profitability than its competitors (-1,030.34 %).
Cybin Inc generated 91.00 % of the combined sales of its peer group, up from 89.77 % a year earlier.
API endpoints for this dataset
Cybin Inc vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Cybin Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Cybin Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Cybin Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Cybin Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 123.7% for Cybin Inc. Cybin Inc's share of combined industry revenue moved from 0.01% to 0.03%, a gain of 0.02 percentage points.
Cybin Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cybin Inc | No | Yes | Yes | Yes |
| Competitors combined (17) | ||||
| Similar Growth & Profitability (8) | 87.50 % (7 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CYBN Stock Performance relative to its Competitors
CYBN Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Alto Neuroscience Inc | 282.9% | Outperformed |
| 2 | Compass Pathways Plc | 282.9% | Outperformed |
| 3 | Nrx Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Pasithea Therapeutics Corp | 282.9% | Outperformed |
| 5 | Sage Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cybin Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Cybin Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Cybin Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Cybin Inc |
167.44 | 159.15 |
 Ataibeckley Inc |
2,651.54 | 4.47 |
 Compass Pathways Plc |
1,482.62 | - |
 Alto Neuroscience Inc |
1,424.78 | - |
 Sage Therapeutics Inc |
543.46 | 70.41 |
 Bright Minds Biosciences Inc |
156.41 | - |
| SUBTOTAL | 6,630.31 | 326.87 |
Sign in to see all competitors of Cybin Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cybin Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cybin Inc's Competitors Named by the Company
Competitive relationships identified from Cybin Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Compass Pathways Plc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Vistagen Therapeutics Inc | Company report | 85% |
| Enveric Biosciences Inc | Company report | 85% |
| Clearmind Medicine Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Cybin Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Cybin Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cybin Inc | 167 | 5,304,933 | -2,712,406 |
| Ataibeckley Inc | 2,652 | 22,144 | -3,308,347 |
| Compass Pathways Plc | 1,483 | - | -1,707,058 |
| Alto Neuroscience Inc | 1,425 | - | -1,399,721 |
| Sage Therapeutics Inc | 543 | 199,462 | -853,244 |
| Bright Minds Biosciences Inc | 156 | - | -164,345 |
| PEERS TOTAL | 6,463 | 169,759 | -1,634,755 |
Cybin Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 490 companies in Cybin Inc's industry classification, broader than the peer set above. Market cap in millions of $.Cybin Inc ranks #0 of 490 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 995, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,278,652 | 24.03 % |
| 2 | Johnson and Johnson | 691,817 | 13.00 % |
| 3 | Abbvie Inc | 521,524 | 9.80 % |
| 4 | Merck and Co Inc | 362,966 | 6.82 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Cybin Inc | 167 | 0.00 % |
Market cap and industry share for the rest of Cybin Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-01-02.
Cybin Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (447 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 38.09 % (avg) | -38.1 pp |
| Operating Margin | 51.73 % | industry median | +95.3 pp |
| EBITDA Margin | -54.45 % | -6.73 % (avg) | -47.7 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 7.49 % (avg) | -7.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Cybin Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (447 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.3x | - |
| EV / EBITDA | - | 15.1x | - |
| P/B | 1.1x | 4.2x | -3.2x |
| Return on Equity | -49.33 % | industry aggregate | -64.52 % |
| Return on Invested Capital | 24.96 % | -9.73 % (avg) | 34.69 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cybin Inc's Strategic Group Map
Cybin Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Cybin Inc's trailing-12-month revenue growth of 123.7% and operating margin of 51.7% compares with an average of 88.6% growth and 17.7% margin across its 8 closest peers by combined growth, margin and ROIC -- Cybin Inc sits above that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Cybin Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 995 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 7.49 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Cybin Inc's dedicated Suppliers and Customers pages, not here.
Cybin Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Cybin Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Cybin Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 95.3 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Return on equity 64.5 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (47.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-23.3% annualized).
Methodology: see Methodology: SWOT Analysis.
Cybin Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cybin Inc | 13.25 | 7.75 | - |
| Ataibeckley Inc | 3.50 | 9.64 | 0.03 |
| Compass Pathways Plc | 1.36 | 1.52 | 0.40 |
| Alto Neuroscience Inc | 17.03 | 17.26 | 0.08 |
| Sage Therapeutics Inc | 1.30 | 8.83 | - |
| Bright Minds Biosciences Inc | 35.50 | 36.10 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cybin Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cybin Inc | Q1 2025 | +123.7 % | - |
| Ataibeckley Inc | Q2 2026 | +137.0 % | - |
| Compass Pathways Plc | Q3 2026 | - | - |
| Alto Neuroscience Inc | Q3 2026 | - | - |
| Sage Therapeutics Inc | Q2 2025 | +265.8 % | - |
| Bright Minds Biosciences Inc | Q3 2025 | - | - |
| PEERS TOTAL | +73.6 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cybin Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cybin Inc | Q1 2025 | - | - |
| Ataibeckley Inc | Q2 2026 | - | - |
| Compass Pathways Plc | Q3 2026 | - | - |
| Alto Neuroscience Inc | Q3 2026 | - | - |
| Sage Therapeutics Inc | Q2 2025 | - | - |
| Bright Minds Biosciences Inc | Q3 2025 | - | - |
Cybin Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cybin Inc | - | - | - |
| Ataibeckley Inc | - | - | - |
| Compass Pathways Plc | - | - | - |
| Alto Neuroscience Inc | - | - | - |
| Sage Therapeutics Inc | - | - | - |
| Bright Minds Biosciences Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cybin Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cybin Inc | - | 1.05 |
| Ataibeckley Inc | - | 592.79 |
| Compass Pathways Plc | - | - |
| Alto Neuroscience Inc | - | - |
| Sage Therapeutics Inc | - | 7.72 |
| Bright Minds Biosciences Inc | - | - |
| PEERS AVERAGE | - | 20.28 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.